Holen Sie sich die Stockscreener-App
40.72
0.83%
0.335
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
1 Reason to Sell DexCom Stock, and 1 Reason to Buy - The Motley Fool
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Yahoo Finance
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com
JMP Securities Reaffirms "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month LowTime to Sell? - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - MSN
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interest - MarketBeat
State Street Corp Acquires 599,304 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year LowShould You Sell? - MarketBeat
3 Things You Need To Know If You Buy CRISPR Therapeutics Today - Barchart
CRISPR Therapeutics stock hits 52-week low at $43.37 - Investing.com
Zacks Research Issues Negative Forecast for CRSP Earnings - MarketBeat
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? - Insider Monkey
Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares - GuruFocus.com
What is William Blair's Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Chardan Capital - MarketBeat
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
CRISPR's CTX112 Cancer Therapy Shows 67% Response Rate in Clinical Trial, Earns FDA Special Status - StockTitan
XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Main Management ETF Advisors LLC Purchases Shares of 14,744 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - AOL
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet - MSN
January 2025 Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
Future-Proofing Growth of Gene Editing Technology Innovation - openPR
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by BNP Paribas Financial Markets - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Fmr LLC - MarketBeat
Crispr Therapeutics CEO Kulkarni sells $826,564 in shares By Investing.com - Investing.com Nigeria
Crispr Therapeutics CEO Kulkarni sells $826,564 in shares - Investing.com India
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth - Seeking Alpha
CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR
Baker BROS. Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Zacks Research Has Bullish Forecast for CRSP FY2024 Earnings - MarketBeat
Loomis Sayles & Co. L P Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? - Yahoo Finance
Learn to Evaluate (CRSP) using the Charts - Stock Traders Daily
Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - MSN
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):